Condition
Recurrent Brain Metastases
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Recruiting2
Active Not Recruiting1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT02429570Not ApplicableActive Not RecruitingPrimary
Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
NCT02896335Phase 2Recruiting
Palbociclib and Pembrolizumab In Central Nervous System Metastases
NCT04690348Phase 2RecruitingPrimary
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
NCT02166658Phase 2Terminated
A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Showing all 4 trials